ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Healight (TM) Safety Study in Critically Ill COVID-19 Patients
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 193247" data-attributes="member: 13851"><p><h3>[URL unfurl="true"]https://irdirect.net/prviewer/release_only/id/4576764[/URL]</h3><h3></h3><h3>December 28, 2020</h3><p></p><p></p><p><em><strong>First Safety Study Utilizing Ultraviolet A Light Catheter as a Prospective Anti-Infective in Critically Ill, Intubated SARS-Cov-2 Patients</strong></em></p><p></p><p><strong>ENGLEWOOD, CO / ACCESSWIRE / December 28, 2020 /</strong> Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs announced the completion of the safety study evaluating the Healight™ ultraviolet A light catheter technology. <strong><u>This single-center, U.S.-based study evaluated the safety and proof of principle of the Healight device in newly intubated critically ill patients on mechanical ventilation diagnosed with COVID-19</u>.</strong></p><p><strong></strong></p><p><strong><u>The data collected from this clinical investigational-use-only study will be presented to the U.S. Food & Drug Administration (FDA) as part of the review process for Healight as a COVID-19 treatment. The results of this study will also be submitted for publication</u>.</strong></p><p></p><p>Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, <strong>"<u>This is an important milestone, and we look forward to continuing discussions with the FDA on the advancement of the Healight technology</u>."</strong></p><p><strong></strong></p><p><strong>The Healight technology platform employs proprietary methods of administering intermittent ultraviolet (UV) A light via a novel respiratory tract device. <u>Pre-clinical findings indicate the technology's significant impact on reducing a wide range of viral and bacterial loads, including the coronavirus HCoV-229E, which is associated with the common cold</u>.<u> Recently published pre-clinical data have been the basis of discussions with the FDA for a path to enable human use for the potential treatment of SARS-CoV-2 in intubated patients in the intensive care unit (ICU)</u>.</strong></p></blockquote><p></p>
[QUOTE="madman, post: 193247, member: 13851"] [HEADING=2][URL unfurl="true"]https://irdirect.net/prviewer/release_only/id/4576764[/URL][/HEADING] [HEADING=2][/HEADING] [HEADING=2]December 28, 2020[/HEADING] [I][B]First Safety Study Utilizing Ultraviolet A Light Catheter as a Prospective Anti-Infective in Critically Ill, Intubated SARS-Cov-2 Patients[/B][/I] [B]ENGLEWOOD, CO / ACCESSWIRE / December 28, 2020 /[/B] Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs announced the completion of the safety study evaluating the Healight™ ultraviolet A light catheter technology. [B][U]This single-center, U.S.-based study evaluated the safety and proof of principle of the Healight device in newly intubated critically ill patients on mechanical ventilation diagnosed with COVID-19[/U]. [U]The data collected from this clinical investigational-use-only study will be presented to the U.S. Food & Drug Administration (FDA) as part of the review process for Healight as a COVID-19 treatment. The results of this study will also be submitted for publication[/U].[/B] Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, [B]"[U]This is an important milestone, and we look forward to continuing discussions with the FDA on the advancement of the Healight technology[/U]." The Healight technology platform employs proprietary methods of administering intermittent ultraviolet (UV) A light via a novel respiratory tract device. [U]Pre-clinical findings indicate the technology's significant impact on reducing a wide range of viral and bacterial loads, including the coronavirus HCoV-229E, which is associated with the common cold[/U].[U] Recently published pre-clinical data have been the basis of discussions with the FDA for a path to enable human use for the potential treatment of SARS-CoV-2 in intubated patients in the intensive care unit (ICU)[/U].[/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Healight (TM) Safety Study in Critically Ill COVID-19 Patients
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top